Compare KZIA & TCBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KZIA | TCBS |
|---|---|---|
| Founded | 1994 | 1934 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.8M | 48.6M |
| IPO Year | 2002 | 2021 |
| Metric | KZIA | TCBS |
|---|---|---|
| Price | $5.91 | $16.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 217.9K | 2.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.20% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.69 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $24.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $15.01 |
| 52 Week High | $17.40 | $20.00 |
| Indicator | KZIA | TCBS |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 48.61 |
| Support Level | $5.45 | $15.85 |
| Resistance Level | $8.05 | $17.37 |
| Average True Range (ATR) | 0.58 | 0.46 |
| MACD | 0.13 | -0.04 |
| Stochastic Oscillator | 61.68 | 11.24 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.